Publications by authors named "Asmaa Ellaithy"
Article Synopsis
- Cabozantinib shows improved overall survival and effectiveness in treating advanced renal cell carcinoma compared to sunitinib and is particularly effective against everolimus.
- A systematic review included data from 967 patients and demonstrated cabozantinib’s superior performance in progression-free survival and tumor response rates.
- While cabozantinib is more effective overall, it may lead to a higher risk of side effects compared to sunitinib, making it a strong candidate for first-line aRCC therapy.